ORZEYFUL (oveporexton) FDA Approval: The First Orexin Agonist for Narcolepsy
The U.S. Food and Drug Administration (FDA) has approved ORZEYFUL (oveporexton), developed by Takeda, on August 5, 2026, making it the first orexin agonist approved for adults living with narcolepsy type 1 (NT1 or narcolepsy with cataplexy) in the United States.
The approval marks a historic milestone for the narcolepsy community and one of the most significant advances in neuroscience and sleep medicine since the discovery of the orexin system nearly three decades ago. ORZEYFUL is the first approved therapy designed to target the underlying biological cause of narcolepsy type 1.
Narcolepsy is a chronic neurological condition that impairs the brain’s ability to regulate the sleep-wake cycle. Symptoms may include excessive daytime sleepiness, cataplexy (muscle paralysis triggered by emotions), vivid hallucinations around sleep, sleep paralysis, and disrupted nighttime sleep.
What Is ORZEYFUL (oveporexton)?
ORZEYFUL (oveporexton) is an oral orexin receptor 2 (OX2R)-selective agonist, developed by Takeda, designed to address the underlying orexin deficiency that causes narcolepsy type 1 by restoring orexin signaling. It is the first FDA-approved orexin agonist, representing a novel treatment approach.
The approval was based on 2 randomized, double-blind, placebo-controlled 12-week studies, FirstLight (NCT06470828) and RadiantLight (NCT06505031), enrolling a combined 273 adults with NT1. See the phase 3 results here.
Orexin (also called hypocretin) is a brain signaling molecule that plays a critical role in promoting wakefulness and maintaining stable transitions between sleep and wake. Most people with narcolepsy type 1 have lost the brain cells that produce orexin, leading to the hallmark symptoms of the condition.
Why This FDA Approval Matters
The discovery of orexin less than 30 years ago transformed scientists’ understanding of how the brain regulates wakefulness, sleep, and REM/dream sleep. The approval of the first orexin agonist demonstrates how basic scientific discovery can ultimately lead to an entirely new class of medications, a powerful example of translating discoveries in the laboratory into treatments with the potential to improve people’s lives.
Orexin has been described as one of the brain’s key regulators of the sleep-wake cycle. Researchers continue to explore whether therapies targeting the orexin system could one day have broader applications in additional neurological, neurodegenerative, or neuropsychiatric conditions. While those possibilities remain under investigation, this first approval represents a historic milestone for neuroscience.
Scientific breakthroughs don’t happen overnight. This reflects decades of fierce determination, from the laboratories where orexin was first discovered and the scientists and drug developers who transformed that discovery into a new class of medicines, to the clinical trial participants who contributed significant time, energy, and trust to make this moment possible. It’s an inspiring reminder of what’s possible when scientific and patient communities move forward together.”
– Julie Flygare, JD
President & CEO, Project Sleep
Person living with narcolepsy type 1
Looking Ahead: The Future of Orexin Agonists
The approval of Takeda’s ORZEYFUL represents the first approval within what is expected to become a growing class of orexin agonist therapies.
Several additional investigational orexin agonists are advancing through clinical development, including alixorexton (Alkermes), cleminorexton (Eli Lilly/Centessa), E2086 (Eisai), BP1.15205 (Harmony Biosciences/Bioprojet), and Lu AH69593 (Lundbeck). While each investigational therapy is unique and research remains ongoing, together they reflect the extraordinary excitement surrounding orexin science.
Researchers are studying these investigational therapies for conditions including narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH). Each program is at a different stage of development. Project Sleep is encouraged to see continued investment across the field, as a robust pipeline of orexin-based therapies offers hope for future treatment options for the sleep disorder community.
To learn more about clinical trial opportunities in the United States, visit Project Sleep’s Participate in Research page. In addition, many international study locations are listed on ClinicalTrials.gov.
Progress Around the World
Narcolepsy affects an estimated three million people worldwide. We are thrilled for our friends in China, where ORZEYFUL recently became the first approved treatment for narcolepsy type 1. We are also excited that regulatory review continues in Japan, where oveporexton received Sakigake designation to accelerate the development and review of innovative medicines.
Project Sleep will continue to share updates as information becomes publicly available regarding other regulatory decisions around the world.
Why Project Sleep’s Work Continues
Although this approval marks an extraordinary milestone, much work remains. Experts believe the majority of people living with narcolepsy remain undiagnosed, and studies report an average delay from symptom onset to diagnosis of approximately 8–15 years. Project Sleep remains committed to advancing education, awareness, research, and advocacy so that more people can access timely diagnosis, support, and emerging treatment options.
Frequently Asked Questions
An orexin agonist is a medication that activates orexin receptors. Orexin is a naturally occurring brain signaling molecule that helps regulate wakefulness, REM sleep, and muscle tone.
ORZEYFUL is approved in the United States for adults with narcolepsy type 1. Always discuss treatment options with your healthcare provider to determine what is appropriate for your individual situation.
FDA approval is an important milestone, but it does not necessarily mean a medication is immediately available to prescribe or receive in the United States.
Following approval, additional steps typically take place before a new medication becomes broadly available. These may include manufacturing and distribution, insurance coverage and reimbursement processes, and launch planning.
Project Sleep encourages people living with narcolepsy to speak with their healthcare provider about whether ORZEYFUL may be an appropriate treatment option and to stay tuned for updates from Takeda regarding product availability. We will also share information with our community as it becomes publicly available.
Not at this time. The current ORZEYFUL FDA approval is for narcolepsy type 1 (NT1 or narcolepsy with cataplexy). However, clinical trials are currently evaluating orexin agonists in people living with narcolepsy type 2 (NT2 or narcolepsy without cataplexy) and idiopathic hypersomnia (IH).
To learn more about clinical trial opportunities in the United States, visit Project Sleep’s Participate in Research page. In addition, many international study locations are listed on ClinicalTrials.gov.
Narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH) are all neurological sleep disorders that can cause excessive daytime sleepiness, but there are important differences. Narcolepsy type 1 involves the symptom, cataplexy: sudden episodes of muscle paralysis or weakness—and is associated with very low levels of the brain chemical orexin (also called hypocretin), which helps regulate sleep and wakefulness.
Narcolepsy type 2 occurs without cataplexy, and its underlying cause is less well understood. Both types of narcolepsy may also involve symptoms such as sleep-related hallucinations, sleep paralysis, and disrupted nighttime sleep. Learn more about NT1 and NT2.
Idiopathic hypersomnia is characterized by persistent excessive daytime sleepiness despite adequate or even prolonged nighttime sleep. People with IH may experience prolonged sleep, extreme difficulty waking, sleep inertia or “sleep drunkenness,” brain fog, and long, unrefreshing naps. Learn more about idiopathic hypersomnia.
Treatment is an individualized process and depends on a person’s symptoms, medical history, and treatment goals. The ORZEYFUL FDA approval marks the first orexin agonist treatment, representing a new class of treatment for adults with narcolepsy type 1.
Other important FDA-approved medications for narcolepsy include wake-promoting medications, stimulants, oxybate therapies, histamine-directed medications, and other treatments that help improve excessive daytime sleepiness and/or reduce cataplexy. In addition to medication, many people benefit from social support, scheduled naps, and personalized lifestyle coping strategies.
To learn more about treatment options for narcolepsy, visit Project Sleep’s narcolepsy treatments page.
At Project Sleep, we believe that no one with narcolepsy should have to feel alone. Narcolepsy affects approximately 1 in every 2,000 people, or an estimated 200,000 Americans and three million people worldwide.
Due to low awareness (even amongst healthcare providers), experts believe that the majority of people living with narcolepsy remain undiagnosed. For those who do receive an accurate diagnosis, studies have reported an average delay from symptom onset to diagnosis of approximately 8–15 years, with some individuals waiting decades.
Narcolepsy is a chronic neurological condition that affects the brain’s ability to regulate the sleep-wake cycle. Symptoms vary by person but may include:
- Excessive daytime sleepiness (EDS): Periods of extreme sleepiness during the day that feel comparable to how someone without narcolepsy would feel after staying awake for 48-72 hours.
- Cataplexy: A unique form of muscle paralysis or weakness, usually triggered by emotions such as laughter, exhilaration, surprise, or anger. The severity of the paralysis varies from a slackening of the jaw or buckling of the knees to falling down. The paralysis may last for a few seconds to several minutes and importantly, the person remains fully conscious (even if unable to speak) during the episode.
- Hypnagogic or hypnopompic hallucinations: Visual, auditory, or tactile hallucinations upon falling asleep or waking up. These can be frightening and confusing to distinguish from reality.
- Sleep paralysis: The inability to move for a few seconds or minutes upon falling asleep or waking up. This may be paired with the vivid hallucinations.
- Disrupted nighttime sleep: Narcolepsy causes physiological instability in both non-REM and REM sleep, leading to frequent spontaneous awakenings and fragmented nighttime sleep.
- Cognitive functioning: Researchers are increasingly examining how narcolepsy affects attention, memory, concentration, mental clarity, and executive functioning, reflecting the importance of cognitive symptoms on daily life.
Learn more in Project Sleep’s Could I Have Narcolepsy? toolkit.
Through Narcolepsy Nerd Alert, Project Sleep provides practical, evidence-based educational resources designed with patients in mind, covering topics such as symptoms, diagnosis, treatment options, driving, napping, school accommodations, workplace accommodations, and everyday life with narcolepsy.
World Narcolepsy Day occurs annually on Sept. 22nd annually and aims to inspire action, increase public knowledge, and elevate the voices of the 3 million people living with narcolepsy worldwide. Together, we can reduce delays in narcolepsy diagnosis, reduce stigma and improve outcomes.
Rising Voices℠ is Project Sleep’s leadership training program for people living with narcolepsy and other sleep disorders to become empowered advocates by sharing their lived experiences with healthcare professionals, researchers, policymakers, media, and their communities.
To be the first to know about opportunities to take action, sign up for Project Sleep e-updates.
Have questions about narcolepsy? Contact the Sleep Helpline
, the first national helpline for people facing sleep issues and sleep disorders in the United States.
Medical Disclaimer: Project Sleep provides educational resources to help people better understand sleep disorders and emerging research. This article is for educational purposes only and is not intended to replace professional medical advice, diagnosis, or treatment. Decisions about medications and other treatments should always be made in partnership with a qualified healthcare provider who can consider your individual medical history, symptoms, and treatment goals.
More Narcolepsy News
ORZEYFUL (oveporexton) FDA Approval: The First Orexin Agonist for Narcolepsy
“The Pitt” Narcolepsy Mention Misses a Major Opportunity for Accurate Representation
Wide Awake and Dreaming, a Narcolepsy Memoir, Selected as the 2026 Stanford SASI Book Club Pick
The post ORZEYFUL (oveporexton) FDA Approval: The First Orexin Agonist for Narcolepsy appeared first on Project Sleep.
Läs hela artikeln: Visa original